A 12-week, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of a Nutraceutical Supplement for Mild to Moderate Non-cystic Acne in Young Adults

Overview

Journal J Clin Aesthet Dermatol

Date 2025 Jan 6

PMID 39758223

Authors

Glynis Ablon

Affiliations

Soon will be listed here.

Abstract

Background: Acne vulgaris is a chronic, inflammatory skin disease of the pilosebaceous unit frequently cited as the most common condition diagnosed and treated by dermatologists. Among the many therapies developed for treating acne, none are effective for all patients and new treatments are always being sought. A commercial nutraceutical formulated with vitamins, minerals and a proprietary blend of botanicals has been used as a safe and effective adjunctive therapy for non-cystic acne (Clear Skin Formula; VitaMedica®).

Objective: The objective of this study was to evaluate the safety and efficacy of this nutraceutical for treating non-cystic acne.

Methods: Subjects randomly received study product (n=26) or placebo capsules (n=14) which were taken daily for 84 days.

Results: Treatment with the nutraceutical supplement decreased mean (SD) inflammatory lesions counts from 21.4 (9.3) to 10.4 (8.1) (=0.0001), decreased non-inflammatory lesion counts from 35.0 (17.1) to 19.5 (13.2) (<0.0001) versus nonsignificant changes for placebo-treated subjects. Mean baseline IGA scores improved by nearly 1 grade from 2.3 (0.5) to 1.4 (0.6) after 84 days of treatment (<0.0001) versus no change for subjects treated with placebo. The clinical improvements corresponded with significant improvements in acne-related quality of life measures. The nutraceutical supplement was well-tolerated.

Conclusion: These results demonstrate this nutraceutical to be safe and effective adjunctive therapy for patients with non-cystic acne. ClinicalTrial.gov Identifier NCT05879406.

References

El-Akawi Z, Abdel-Latif N, Abdul-Razzak K . Does the plasma level of vitamins A and E affect acne condition?. Clin Exp Dermatol. 2006; 31(3):430-4. DOI: 10.1111/j.1365-2230.2006.02106.x. View

Dessinioti C, Katsambas A . Antibiotics and Antimicrobial Resistance in Acne: Epidemiological Trends and Clinical Practice Considerations. Yale J Biol Med. 2022; 95(4):429-443. PMC: 9765333. View

Del Rosso J, Farris P, Harper J, Baldwin H, Hazan A, Raymond I . New Insights Into Systemic Drivers of Inflammation and Their Contributions to the Pathophysiology of Acne. J Drugs Dermatol. 2024; 23(2):90-96. DOI: 10.36849/JDD.8137. View

Michaelsson G . Decreased concentration of selenium in whole blood and plasma in acne vulgaris. Acta Derm Venereol. 1990; 70(1):92. DOI: 102340/000155557092. View

Bottega R, Persico I, De Seta F, Romano F, Lorenzo G . Anti-inflammatory properties of a proprietary bromelain extract (Bromeyal™) after simulated gastrointestinal digestion. Int J Immunopathol Pharmacol. 2021; 35:20587384211034686. PMC: 8366142. DOI: 10.1177/20587384211034686. View

Podgorska A, Puscion-Jakubik A, Markiewicz-Zukowska R, Gromkowska-Kepka K, Socha K . Acne Vulgaris and Intake of Selected Dietary Nutrients-A Summary of Information. Healthcare (Basel). 2021; 9(6). PMC: 8226785. DOI: 10.3390/healthcare9060668. View

Reynolds R, Yeung H, Cheng C, Cook-Bolden F, Desai S, Druby K . Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024; 90(5):1006.e1-1006.e30. DOI: 10.1016/j.jaad.2023.12.017. View

Burgess C, Gold M, Farris P, Hazan A, Raymond I . A Novel Systems-Wide Approach in Addressing Acne with a Multi-Targeting Nutraceutical. J Drugs Dermatol. 2024; 23(3):160-167. DOI: 10.36849/jdd.8138. View

Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden J . New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009; 60(5 Suppl):S1-50. DOI: 10.1016/j.jaad.2009.01.019. View

10.

Butawan M, Benjamin R, Bloomer R . Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement. Nutrients. 2017; 9(3). PMC: 5372953. DOI: 10.3390/nu9030290. View

11.

Zaenglein A, Pathy A, Schlosser B, Alikhan A, Baldwin H, Berson D . Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016; 74(5):945-73.e33. DOI: 10.1016/j.jaad.2015.12.037. View

12.

Walsh T, Efthimiou J, Dreno B . Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infect Dis. 2016; 16(3):e23-33. DOI: 10.1016/S1473-3099(15)00527-7. View

13.

Sardana K, Garg V . An observational study of methionine-bound zinc with antioxidants for mild to moderate acne vulgaris. Dermatol Ther. 2010; 23(4):411-8. DOI: 10.1111/j.1529-8019.2010.01342.x. View

14.

Nasri H, Bahmani M, Shahinfard N, Moradi Nafchi A, Saberianpour S, Kopaei M . Medicinal Plants for the Treatment of Acne Vulgaris: A Review of Recent Evidences. Jundishapur J Microbiol. 2016; 8(11):e25580. PMC: 4740760. DOI: 10.5812/jjm.25580. View

15.

Dattner A . From medical herbalism to phytotherapy in dermatology: back to the future. Dermatol Ther. 2003; 16(2):106-13. DOI: 10.1046/j.1529-8019.2003.01618.x. View

16.

Habeshian K, Cohen B . Current Issues in the Treatment of Acne Vulgaris. Pediatrics. 2020; 145(Suppl 2):S225-S230. DOI: 10.1542/peds.2019-2056L. View

17.

Miazga-Karska M, Michalak K, Ginalska G . Anti-Acne Action of Peptides Isolated from Burdock Root-Preliminary Studies and Pilot Testing. Molecules. 2020; 25(9). PMC: 7248785. DOI: 10.3390/molecules25092027. View

18.

Saurat J, Halioua B, Baissac C, Perez Cullell N, Ben Hayoun Y, Saint Aroman M . Epidemiology of acne and rosacea: A worldwide global study. J Am Acad Dermatol. 2024; 90(5):1016-1018. DOI: 10.1016/j.jaad.2023.12.038. View

19.

Salameh F, Shumaker P, Goodman G, Spring L, Seago M, Alam M . Energy-based devices for the treatment of Acne Scars: 2022 International consensus recommendations. Lasers Surg Med. 2021; 54(1):10-26. DOI: 10.1002/lsm.23484. View

20.

Cook M, Perche P, Feldman S . Oral Vitamin A for Acne Management: A Possible Substitute for Isotretinoin. J Drugs Dermatol. 2022; 21(6):683-686. DOI: 10.36849/JDD.6781. View